Occipital nerve stimulation decreases attack frequency of intractable chronic cluster headache: Lancet
The occipital nerve stimulation provided relief to the patients with medically intractable chronic cluster headache, as it substantially reduced the attack recurrence, according to a study published in The Lancet neurology journal.
Chronic cluster headaches are a type of painful headaches that occur in regular patterns of cluster periods. It is characterized by migraine-like nausea and aura. It disturbs one's sleep at night as it generally causes severe pain in or around one eye on one side of the head. These episodes of frequent attacks are also called cluster periods, which can last from weeks to months. Occipital nerve stimulation (ONS) has shown promising results in small uncontrolled trials in patients with medically intractable chronic cluster headache (MICCH).
A study was conducted by a group of researchers from the Netherlands, to demonstrate if occipital nerve stimulation could prove to be an efficient treatment for patients with medically intractable chronic cluster headache.
The researchers conducted a controlled clinical trial at a total of six hospitals, four hospitals in the Netherlands, one hospital in Belgium, one in Germany, and one in Hungary. After 12 weeks' baseline observation, a total of 150 patients were enrolled with a history of being non-responsive to at least three standard preventive drugs between October 12, 2010, to December 3, 2017. They were randomly allocated to treatment 131 (87%) to treatment for 24 weeks; out of which 65 (50%) patients were assigned to 100% Occipital nerve stimulation and 66 (50%) were assigned to 30% Occipital nerve stimulation. One of the 66 patients assigned to 30% ONS was not implanted and was therefore excluded from the intention-to-treat analysis. As occipital nerve stimulation causes paraesthesia, preventing masked comparison versus placebo, they compared high-intensity versus low-intensity occipital nerve stimulation, which is hypothesized to cause similar paraesthesia, but with different efficacy. The primary outcome was the weekly mean attack frequency in weeks 21-24 compared with baseline across all patients and if a decrease was shown, to show a group-wise difference.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.